Eton Pharmaceuticals Enters Asset Purchase Agreement To Acquire Increlex (Mecasermin Injection) From Ipsen; No Terms Disclosed
Eton Pharmaceuticals Enters Asset Purchase Agreement To Acquire Increlex (Mecasermin Injection) From Ipsen; No Terms Disclosed
Increlex is a biologic product used to treat children and adolescents from 2- to 18-years-old who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD) because their bodies do not make enough insulin-like growth factor 1 (IGF-1).
Increlex是一種生物製品，用於治療2至18歲患有嚴重原發性胰島素樣生長因子1缺乏症（SPIGFD）的兒童和青少年，因爲他們的身體無法產生足夠的胰島素樣生長因子1（IGF-1）。
The medicine is approved in 40 territories, including the United States (U.S.) and the European Union (EU). It is estimated that approximately 200 patients in the United States and 900-1,000 patients in Europe live with SPIGFD. Increlex is the only treatment approved by the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) for SPIGFD.
這種藥物已獲得40個地區的批准，包括美國和歐洲聯盟（歐盟）。據估計，美國約有約200名患有SPIGFD的患者，歐洲約有900-1,000名患者。 Increlex是美國食品和藥品管理局（FDA）或歐洲藥品管理局（EMA）批准用於治療SPIGFD的唯一治療方法。
Ipsen reported global sales for Increlex of €17.3 million in 2023.
艾珊報告稱，2023年Increlex在全球的銷售額爲1,730萬歐元。
譯文內容由第三人軟體翻譯。
